Azole Resistance of Candida glabrata in a Case of Recurrent Fungemia
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
We describe a case of recurrent Candida glabrata fungemia that became unresponsive to fluconazole treatment. Posttreatment isolates from blood and vaginal cultures of the immunocompetent patient were azole resistant and exhibited upregulated expression of CgCDR1 / CgCDR2 efflux pumps compared to the original isolates. Amphotericin B therapy eradicated the infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the second (BPY41) was azole resistant (fluconazole MIC, >256 μg/ml).”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [28]
In the citing paper
“BPY41 exhibits cross-resistance to all azoles tested (fluconazole, itraconazole, and voriconazole).”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [28]
In the citing paper
“The first isolate (BPY40) was azole susceptible (fluconazole MIC, 4 μg/ml)”
From Loss of Mitochondrial Functions Associated with Azole Resistance in Candida glabrata Results in Enhanced Virulence in Mice (2011) · cites this paper as [28]
In the citing paper
“petite C. glabrata shows resistance to fungistatic azole drugs due to overexpression of ABC transporters (CDR1, CDR2, and SNQ2) and their transcriptional regulator (PDR1)”
From Overlooked Candida glabrata petites are echinocandin tolerant, induce host inflammatory responses, and display poor in vivo fitness (2023) · cites this paper as [12]
In the citing paper
“the candidemia patient infected by BYP41 was successfully treated with amphotericin B (12)”
From Overlooked Candida glabrata petites are echinocandin tolerant, induce host inflammatory responses, and display poor in vivo fitness (2023) · cites this paper as [12]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Infectious Diseases Society of America
Enders, J. F. (1969) · Journal of Infectious Diseases · doi:10.1093/infdis/119.3.317 · Cited by 3,286
Manual of Clinical Microbiology, 7th ed.
Balows, A. (2000) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00102-9 · Cited by 1,613
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337 · cited 1×
“glabrata, upregulation of the ABC transporter genes CgCDR1 and CgCDR2 is primarily responsible for acquired azole resistance that remains stable over time (7, 12).”
BackgroundSanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319 · cited 7×
“Posttreatment isolates from blood and vaginal cultures of the immunocompetent patient were azole resistant and exhibited upregulated expression of CgCDR1/CgCDR2 efflux pumps compared to the original isolates.”
BackgroundMethodInfluentialSelf-citationCandida, Cryptococcus, and Other Yeasts of Medical Importance
Howell, S. A., & Hazen, K. C. (2011) · Manual of Clinical Microbiology · doi:10.1128/9781555816728.ch115 · Cited by 246
Mechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis
Bennett, J. E., Izumikawa, K., & Marr, K. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1773-1777.2004 · Cited by 217 · cited 3×
“glabrata clinical isolates (2, 11, 13) and in vitro (3).”
BackgroundMultilocus Sequence Typing of Candidaglabrata Reveals Geographically EnrichedClades
Dodgson, A. R., Pujol, C., Denning, D. W., Soll, D. R., & Fox, A. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.12.5709-5717.2003 · Cited by 190
Cited by
Pfaller, M. A., Andes, D., Diekema, D. J., Espinel-Ingroff, A., & Sheehan, D. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.09.002 · Cited by 314
Ferrari, S., Sanguinetti, M., De Bernardis, F., Torelli, R., Posteraro, B., Vandeputte, P., & Sanglard, D. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01271-10 · Cited by 144
“BPY40 and BPY41, described as isolates T0 and T1 in the original publication (28), respectively, belong to a series of isolates that were obtained from two different body sites (blood and vagina) at different times.”
BackgroundMethodInfluentialSelf-citationTorelli, R., Posteraro, B., Ferrari, S., La Sorda, M., Fadda, G., Sanglard, D., & Sanguinetti, M. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06143.x · Cited by 141
Self-citationPfaller, M. A., Andes, D., Arendrup, M. C., Diekema, D. J., Espinel-Ingroff, A., Alexander, B. D., Brown, S. D., Chaturvedi, V., Fowler, C. L., Ghannoum, M. A., et al. (2011) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2011.03.002 · Cited by 130
“parapsilosis isolates were found to have reduced susceptibility or resistance to both fluconazole and voriconazole, and to other azoles including itraconazole and posaconazole (Alexander et al., 2005; Magill et al., 2006; Moudgal et al., 2005; Panckal et al., 2006; Posteraro et al., 2006).”
BackgroundEspinel-Ingroff, A., Pfaller, M. A., Bustamante, B., Canton, E., Fothergill, A., Fuller, J., Gonzalez, G. M., Lass-Flörl, C., Lockhart, S. R., Martin-Mazuelos, E., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02615-13 · Cited by 105
Munin, E., Giroldo, L. M., Alves, L. P., & Costa, M. S. (2007) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2007.04.011 · Cited by 111
“However, there is an explosion in the number of reports relating the resistance to all the available antifungal agents [16–23].”
BackgroundEmergence and evolution of virulence in human pathogenic fungi
Siscar-Lewin, S., Hube, B., & Brunke, S. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2021.12.013 · Cited by 75
Tumbarello, M., Sanguinetti, M., Trecarichi, E. M., La Sorda, M., Rossi, M., de Carolis, E., de Gaetano Donati, K., Fadda, G., Cauda, R., & Posteraro, B. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn381 · Cited by 53
Self-citationCarvalho, G. G., Felipe, M. P., & Costa, M. S. (2009) · The Journal of Microbiology · doi:10.1007/s12275-009-0059-0 · Cited by 55
Risk factors for late recurrent candidaemia. A retrospective matched case–control study
Muñóz, P., Vena, A., Valerio, M., Álvarez-Uría, A., Guinea, J., Escribano, P., & Bouza, E. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.10.023 · Cited by 50
“To our knowledge, only one retrospective study [13] and a limited number of single cases [14–16] or very short”
BackgroundFungal Profile of Vulvovaginal Candidiasis in a Tertiary Care Hospital
Kalaiarasan, K. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/23578.9475 · Cited by 38
“Posteraro B, Tumbarello M, La Sorda M, Spanu T, Trecarichi EM, De Bernardis F, [34] et al.”
BackgroundSiscar-Lewin, S., Gabaldón, T., Aldejohann, A. M., Kurzai, O., Hube, B., & Brunke, S. (2021) · mBio · doi:10.1128/mbio.01128-21 · Cited by 36
“glabrata described so far have been mainly isolated from azole-treated patients (19, 22).”
BackgroundResultInfluentialAloe vera extract reduces both growth and germ tube formation by Candida albicans
Bernardes, I., Rodrigues, M. P. F., Bacelli, G. K., Munin, E., Alves, L. P., & Costa, M. S. (2011) · Mycoses · doi:10.1111/j.1439-0507.2011.02079.x · Cited by 42
Chen, T., Chen, Y., Chen, Y., & Lu, P. (2012) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2011.11.011 · Cited by 36
Arastehfar, A., Daneshnia, F., Hovhannisyan, H., Fuentes, D., Cabrera, N., Quinteros, C., Ilkit, M., Ünal, N., Hilmioğlu-Polat, S., Jabeen, K., et al. (2023) · mBio · doi:10.1128/mbio.01180-23 · Cited by 27
“The appearance of petite mutants has also been noted in clinical samples obtained from patients infected with Candida glabrata (2, 12), a prominent human fungal pathogen more closely related to S. cerevisiae than to C. albicans (13).”
BackgroundResultInfluentialRosseti, I. B., Wagner, C., Fachinetto, R., Taube, P. S., & Costa, M. S. (2010) · Mycoses · doi:10.1111/j.1439-0507.2010.01888.x · Cited by 19
Zilli, D. M. W., Lopes, R. G., Júnior, S. L. A., Barros, L. M., Miletti, L. C., & Stambuk, B. U. (2015) · Microbiological Research · doi:10.1016/j.micres.2015.06.008 · Cited by 16
“…susceptibility to commonly used antifungal agents, or even because of increasing occurrence of drug-resistant strains, contributing to the high mortality rates observed for C. glabrata bloodstream infections (Bouchara et al. 2000; Bennett et al. 2004; Posteraro et al. 2006; Panackal et al. 2006).”
BackgroundCandidose na medicina veterinária: um enfoque micológico, clínico e terapêutico
de Brito, É. H. S., Fontenelle, R. O. D. S., Brilhante, R. S. N., Cordeiro, R. D. A., Sidrim, J. J. C., & Rocha, M. F. G. (2009) · Ciência Rural · doi:10.1590/s0103-84782009000900046 · Cited by 24
Recurrent Candidemia: Trends and Risk Factors Among Persons Residing in 4 US States, 2011–2018
Seagle, E. E., Jackson, B. R., Lockhart, S. R., Jenkins, E. N., Revis, A., Farley, M. M., Harrison, L. H., Schaffner, W., Markus, T. M., Pierce, R. A., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac545 · Cited by 14
Okamoto, M., Nakano, K., Takahashi-Nakaguchi, A., Sasamoto, K., Yamaguchi, M., Teixeira, M. C., & Chibana, H. (2023) · Journal of Fungi · doi:10.3390/jof9020240 · Cited by 11
“Mutations in the mitochondrial genome or loss of mitochondria cause the so-called petite phenotype, observed in clinical isolates obtained from patients treated with azoles [15,16] or upon in vitro exposure to high concentrations of azoles [11].”
BackgroundMolecular epidemiology of late recurrent candidaemia—a population-based study in Iceland
Ásmundsdóttir, L. R., Erlendsdóttir, H., Gísladóttir, A., & Gottfreðsson, M. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03595.x · Cited by 12
“Other studies of recurrent candidaemia have reported an interval from 1 to 6 months [14–17], whereas persistent Candida prosthetic valve endocarditis has been reported to occur up to 3 years following the initial infection [25].”
BackgroundNew developments in the antifungal susceptibility testing of Candida
Pfaller, M. A. (2008) · Current Fungal Infection Reports · doi:10.1007/s12281-008-0019-x · Cited by 10
Candidiasis mucocutánea. Una revisión
Villanueva-Reyes, J. D. P., & Arenas, R. (2007) · Revista mexicana de micología · Cited by 11
Sucu, M., Ünal, N., Karakoyun, A. S., Şahin, İ. N., Bingöl, O., Hüner, F., Uzay, F. İ., Ünal, İ., Metin, D. Y., & İlkit, M. (2025) · Journal of Fungi · doi:10.3390/jof11020092 · Cited by 1
“Isolating and identifying such phenotypes is extremely important during treatment, and continuing azole therapy will favor the selection of the pathogen population, which can result in therapeutic failure and poor clinical outcomes [19–21].”
Bifonazole in vitro activity and its azole-parallel resistance in clinical yeast isolates
Czaika, V. A., Tietz, H. J., & Schmalreck, A. (2014) · JOURNAL OF ADVANCES IN BIOLOGY · doi:10.24297/jab.v6i1.5463
Pós-Graduação, P. D., Eduardo, C., & Teixeira, C. (2014) · Cited by 1
Emerging Resistance Among Candida Species: Trends and Treatment Considerations for Candidemia
Lee, I., & Zaoutis, T. E. (2007) · Infectious disease and therapy · doi:10.3109/9781420017236.012
Molecular Characterization of Fungal Drug Resistance
Sanguinetti, M., Posteraro, B., & Posteraro, P. (2011) · CRC Press eBooks · doi:10.1201/b11375-110
Self-citationNucleic Acid-Based Panfungal Detection
Preuner, S., & Lion, T. (2011) · CRC Press eBooks · doi:10.1201/b11375-109
Ali, M., & Al-Ezzy, A. I. A. (2026) · Diyala Journal for Veterinary Sciences · doi:10.71375/djvs.2026.04105
Metadata
- Authors
- Posteraro, B., Tumbarello, M., La Sorda, M., Spanu, T., Trecarichi, E. M., De Bernardis, F., Scoppettuolo, G., Sanguinetti, M., & Fadda, G.
- Affiliations
- Departments of Microbiology
- Università Cattolica del Sacro Cuore (IT)
- Department of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy
- Corresponding author
- Sanguinetti, Maurizio
- ORCID
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2006-08
- Volume
- 44
- Issue
- 8
- Pages
- 3046-3047
- ISSN
- 0095-1137 (ISSN-L)
- 1098-660X
- OpenAlex
- W1975475744
- Cited by
- 30
- References
- 18
- Citations by year
- 2025: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2017: 1 · 2015: 2 · 2014: 3 · 2012: 1
- FWCI
- 1.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Clinical Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida glabrata, azole resistance, fluconazole resistance, efflux pumps, amphotericin B, immunocompetent patient, antifungal treatment failure
- MeSH terms
- Adult, Amphotericin B, Antifungal Agents, Azoles, Blood, Candidiasis, Female, Genes, Fungal, Humans, Recurrence, Vagina, Gene Expression Regulation, Fungal, Fungemia, Drug Resistance, Fungal, Candida glabrata
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.